Advertisement

Topics

Novartis to buy cancer specialist AAA for $3.9 billion

07:10 EDT 30 Oct 2017 | Reuters
Related Biotechnology, Pharmaceutical and Healthcare News

ZURICH (Reuters) - Novartis is buying French-based Advanced Accelerator Applications (AAA) for $3.9 billion, giving the Swiss drugmaker a platform in radiopharmaceuticals and access to a new therapy for the kind of cancer that killed Steve Jobs.

Original Article: Novartis to buy cancer specialist AAA for $3.9 billion

NEXT ARTICLE

More From BioPortfolio on "Novartis to buy cancer specialist AAA for $3.9 billion"

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search
Advertisement
 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


News Quicklinks

Search Biotech, Medical and Healthcare News

Popular Biotech, Medical and Healthcare News

Biotech News by Article Type

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches


BioPortfolio Limited Social Media
Publish Content Agreements
Tools Help

HON Code certificate This site complies with the HONcode standard for trustworthy health information:
Verify here.

The information provided by BioPortfolio.com is not a substitute for professional medical advice, diagnosis or treatment. The BioPortfolio site is sponsored BioPortfolio Limited with offices at Stafford House, 10 Prince of Wales Road, Dorchester, DT1 1PW, England. If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of “Fair Use” and legitimately infringes on your or your client's copyright we may be contacted concerning copyright matters at: priority@bioportfolio.com.
All rights reserved. All other trademarks recognized. Copyright © 1997-2017 BioPortfolio Limited. Site developed by Alacrify Ltd.